Untitled

Division of Bioconvergence TechnologyIntegrative OmicsResearch CenterRESEARCHERSOhsuk Kwon oskwon@kribb.re.krFunctional genomics and synthetic biology ofprokaryotesSignal transduction and molecular genetic engineeringKwang-Lae Hoe kwanghoe@kribb.re.krFunctional genomics, synthetic biology, and HCS drugtarget screeningGenome-wide gene deletion of fission yeastYoungwoo Park ywpark@kribb.re.krTherapeutic human antibodies and validation of newcancer targetsHuman antibodies and receptor fusion proteins forRheumatoid ArthritisDong-uk Kim kimdongu@kribb.re.krYeast-based HTS systemDrug-protein interaction using network algorithmDoo-Byoung Oh dboh@kribb.re.krDevelopment of glycan remodeling technologyGlycomics study for stem cell and cellular senescenceRESEARCH AREASGenomics-based gene deletion researchConstruction of genome-wide deletion in fission yeast forfunctional genomics and drug target screeningProteomics-based therapeutic antibody researchTarget validation and confirmation of cancer targets,production of human antibodies, identification ofrheumatoid arthritis modulatorsGlycomics-based cellular remodeling researchIntegrated genomic analysis of the metabolic regulatorynetworks and stress response mechanisms; developmentof glycan remodeling technologies and high-throughputglycan analysis systemsDirector Ohsuk KwonT + 82-42-860-4459F + 82-42-860-4594E oskwon@kribb.re.krACHIEVEMENTSConstruction of genome-wide gene deletion in fission yeastAlmost 99% of the fission yeast genome was deleted, and their importance wasconfirmed through tetrad analysis. Using the mutants and GeneChip, a drug targetscreening system was established.Development of a yeast cell factory for the production of therapeutic proteinsWhole genome sequence of the methylotrophic yeast H. polymorpha was determinedand applied to functional genomics and transcriptomics studies, which are useful for cellfactory remodeling. In addition, glycosylation pathways were elucidated and reconstructedto produce human-compatible high-value-added therapeutic glycoproteins.Development of human antibodies for novel cancer therapeutic targetsThe first fully human neutralizing antibodies for TMPRSS4 and CD9 (novel targets forcancer angiogenesis and metastasis), were evaluated and developed for cancerdiagnosis and treatment.SELECTED PUBLICATIONSOhsuk Kwon (Corresponding) Appl Microbiol Biotechnol. 88(2):497-507.Characterization of alcohol dehydrogenase 1 of the thermotolerant methylotrophic yeastHansenula polymorphaOhsuk Kwon (Co-corresponding) Appl Microbiol Biotechnol. 88(4):893-903.Construction of an in vitro trans-sialylation system: surface display of Corynebacteriumdiphtheriae sialidase on Saccharomyces cerevisiaeOhsuk Kwon (Co-corresponding) J Biochem. 147(4):523-33.Identification and functional characterization of the NanH extracellular sialidase fromCorynebacterium diphtheriaeYoungwoo Park (Co-corresponding) J Immunol. 185(8):4921-7.Soluble CD93 induces differentiation of monocytes and enhances TLR responsesKwang-Lae Hoe (Corresponding) Nat Biotechnol. 28(6):617-23.Analysis of a genome-wide set of gene deletions in the fission yeast SchizosaccharomycespombeOur goal is to develop platform technologies useful for the production of next-generation bio-therapeutics andhigh-value-added omics products, such as genome-deleted yeast strains, human therapeutic antibodies, and glycosylatedtherapeutic proteins. We focus on intelligent cellular engineering and molecular reconstruction technologies, based on anunderstanding of bio-phenomena on a systemic level and an integrated analysis of various omics data, such as functionalgenomics, proteomics and glycomics.24 KRIBB Annual Report 2010KRIBB Annual Report 2010 25